Inhibikase Therapeutics (Inhibikase Therapeutics) Total Current Assets : $10.81 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Inhibikase Therapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Inhibikase Therapeutics's total current assets for the quarter that ended in Mar. 2024 was $10.81 Mil.

Inhibikase Therapeutics Total Current Assets Historical Data

The historical data trend for Inhibikase Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibikase Therapeutics Total Current Assets Chart

Inhibikase Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

0.04

14.78

42.47

24.37

14.21

Inhibikase Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															27.63	21.98	17.55	14.21	10.81

Inhibikase Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Inhibikase Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	13.252	+	0	+	0	+	0.959
	=	14.21

Inhibikase Therapeutics's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	9.749	+	0	+	0	+	1.059
	=	10.81

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Inhibikase Therapeutics (NAS:IKT) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Inhibikase Therapeutics's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	9.749	-	4.291	+	0.75 * 0	+	0.5 * 0
=	5.46

Inhibikase Therapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Inhibikase Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibikase Therapeutics (Inhibikase Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibikase Therapeutics Inc (NAS:IKT) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA, USA, 30339

Website

https://www.inhibikase.com

Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.

Executives

Paul C Grint	director	7757 DOUGHILL COURT, SAN DIEGO CA 92127
Dennis N Berman	director	9605 SCRANTON RD, STE 240, SAN DIEGO CA 92121
Roy Lester Freeman	director	256 SUMMIT AVE, BROOKLINE MA 02446
Gisele Dion	director	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Milton H. Werner	director, 10 percent owner, officer: President and CEO	3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339
Joseph Frattaroli	officer: Cheif Financial Officer
Elizabeth G. O'farrell	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Daniel Kalman	10 percent owner	3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339